Profile: Resverlogix Corp. is a biotechnology company focused on developing novel therapies for primarily cardiovascular disease, cancer and fibrotic conditions. Our NexVas™ Plaque Regression is a technology platform for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular diseases. Our NexVas™ Vascular Inflammation is a discovery stage technology for the development of drugs that target molecular markers of inflammation. Our TGF-â Shield™ is a research stage therapeutic for the treatment of grievous proliferative diseases, such as cancer and fibrotic conditions.